Evaluation of baseline body-weight dosing of 90Y ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non- Hodgkin’s lymphoma - Wiseman, G; Conti, P; Vo, K (Blood, 2004)